Effect of DC-CIK cellular immunotherapy combined with chemotherapy on clinical efficacy and immune function in patients with advanced ovarian cancer
PENG Juan1 CUI Manman2
1.Department of Obstetrics and Gynecology, Xindu District People′s Hospital of Chengdu, Sichuan Province, Chengdu 610501, China;
2.Department of Gynaecology, Sichuan Provincial People′s Hospital, Sichuan Province, Chengdu 610072, China
Abstract：Objective To explore the effect of dendritic cell-cytokine induced killer cell (DC-CIK) immunotherapy combined with chemotherapy for patients with advanced ovarian cancer and its influence on immune function. Methods A total of 70 patients with advanced ovarian cancer in Xindu District People′s Hospital of Chengdu from January 2015 to December 2017 was divided into two groups according to the random number table method. The control group (n = 35) was treated with Paclitaxel combined with Cisplatin, and the observation group (n = 35) was treated with DC-CIK immunotherapy on the base of control group. Continuous treatment for three courses, and follow up for 6 months, the clinical efficacy between two groups was compared. The comparisons of immune function indexes such as CD3+, CD4+, CD8+, CD19, CD16+CD56+ between two groups before and after treatment was conducted. The adverse reactions during the course of treatment were recorded and compared between the two groups. Results Six months after followed up, the disease control rate and objective remission rate in the observation group were higher than those in the control group, the differences were statistically significant (P < 0.05). The liver dysfunction and bone marrow suppression in the observation group were respectively lower than those in the control group, and the total incidence of adverse reactions in the observation group was lower than that in the control group, the differences were statistically significant (P < 0.05). After treatment, the levels of CD3+, CD4+, CD19 and CD16+CD56+ in two groups were significantly higher than those before treatment, and CD8+ level was lower than that before treatment, and the levels of CD3+, CD4+, CD19 and CD16+CD56+ in the observation group were higher than those in the control group, while the CD8+ level in the observation group was lower than that in the control group, the differences were statistically significant (P < 0.05). Conclusion DC-CIK cell immunotherapy combined with chemotherapy can significantly improve the clinical efficacy and enhance immune function, which has fewer adverse reactions and worthy of clinical promotion.
彭娟1 崔慢慢2. DC-CIK细胞免疫治疗联合化疗治疗晚期卵巢癌的效果及对免疫功能的影响[J]. 中国医药导报, 2019, 16(17): 59-62.
PENG Juan1 CUI Manman2. Effect of DC-CIK cellular immunotherapy combined with chemotherapy on clinical efficacy and immune function in patients with advanced ovarian cancer. 中国医药导报, 2019, 16(17): 59-62.
[1] 叶文凤，徐永娟，蒋敬庭.黏蛋白16在卵巢癌中的研究进展[J].临床检验杂志，2016，34（12）：931-933.
[2] 陈淑君，张勇，周玉梅，等.CT引导下穿刺活检对进展期卵巢癌的诊断价值[J].齐鲁医学杂志，2016，31（6）：655-657.
[3] 李新迪，孟凡旭，王欣，等.DC-CIK细胞免疫疗法对卵巢癌患者免疫功能的影响及临床意义[J].中国实验诊断学，2014，18（2）：283-286.
[4] 段文丽，王峰，张燕，等.CIK联合化疗对卵巢癌疗效的Meta分析[J].中国医药导报，2017，14（29）：80-84.
[5] 郭洁群，邢艳霞，李富娟，等.DC-CIK治疗对晚期卵巢癌患者肿瘤标志物和T细胞亚群的影响[J].海南医学院学报，2016，22（20）：2451-2454.
[6] 赵海燕，苏乌云，呼群，等.DC-CIK联合化疗治疗晚期非小细胞肺癌的疗效及对免疫功能的影响[J].现代生物医学进展，2017，17（13）：2560-2564.
[7] 张勇.DC-CIK辅助治疗对老年晚期卵巢癌病人T细胞亚群和生活质量的影响[J].实用老年医学，2017，31（3）：257-260.
[8] Rosendahl M，Hogdall CK，Mosgaard BJ. restaging and survival analysis of 4036 ovarian cancer patients according to the 2013 FIGO classification for ovarian，fallopian tube，and primary peritoneal cancer [J]. Int J Gynecol Cancer，2016，26（4）：680-687.
[9] 申婧，曹海英.紫杉醇联合顺铂治疗晚期卵巢癌患者的疗效及对免疫功能的影响[J].中国肿瘤临床与康复，2016， 23（7）：790-793.
[10] Torre LA，Bray F，Siegel RL，et al. Global cancer statistics，2012 [J]. CA Cancer J Clin，2015，65（2）：87-108.
[11] 李晓河，谢明祥.CIK及其对肿瘤治疗研究进展[J].贵州医药，2015，39（10）：943-946.
[12] 杨舒心，胡方方，刘慧萍，等.CD44在卵巢癌细胞增殖及复发和耐药中作用[J].中华实用诊断与治疗杂志，2017， 31（12）：1164-1166.
[13] 钟姗姗，狄文.Olaparib靶向治疗晚期卵巢癌的研究进展[J].国际妇产科学杂志，2017，44（06）：677-680，694.
[14] Gao D，Li C，Xie X，et al. Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients [J]. PLoS One，2014，9（4）：e93886.
[15] Jiang N，Qiao G，Wang X，et al. Dendritic cell/cytokine-induced killer cell immunotherapy combined with S-1 in patients with advanced pancreatic cancer：a prospective study [J]. Clin Cancer Res，2017，23（17）：5066-5073.
[16] 王璐，杨文静.DC-CIK细胞免疫治疗联合化疗对晚期卵巢癌患者疗效及血清CD133、DDX4水平的影响[J].中国计划生育学杂志，2017，25（5）：304-307.
[17] Zheng C，Yu G，Wang H，et al. Meta-analysis of chemotherapy and dendritic cells with cytokine-induced killer cells in the treatment of non-small-cell lung cancer[J]. Int J Clin Exp Med，2015，8（8）：14527-14537.
[18] 魏西翠，王惠霞，贾汝臻，等.DC-CIK细胞免疫疗法治疗非小细胞肺癌患者的效果及对相关指标的影响[J].疑难病杂志，2018，17（5）：476-479，485.
[19] 翟军厚，陈凤军.化疗与生物免疫疗法治疗胃癌的疗效及对循环肿瘤细胞（CTC）的影响[J].中国现代医生，2017，55（12）：25-27.
[20] Gislefoss RE，Langseth H，Bolstad N，et al. HE4 as an early detection biomarker of epithelial ovarian cancer：investigations in prediagnostic specimens from the janus serumbank [J]. Int J Gynecol Cancer，2015，25（9）：1608-1615.
2019, Vol. 16 
京公网安备 11010502046598号